Of the four Congressional bills aimed at providing small companies with new fundraising options, H.R. 1070 – which would allow private firms to raise up to $50 million publicly and trade their shares without the expense of becoming a reporting company – is likely to have the most immediate impact on biotech. Read More
It seemed like a good idea at the time. Run a Phase II clinical trial and reduce your costs by as much as 10-fold. A top academic medical center in India charges only $1,500 to $2,000 per case report, less than one tenth the cost at a second-tier U.S. medical center. And trends show a majority of clinical study sites are now located outside the U.S., many in developing countries, especially Eastern Europe, Russia and India. Read More
FinancingsAdventrx Pharmaceuticals Inc. raised $17 million in a public offering of stock and warrants.Agios Pharmaceuticals Inc. raised $78 million in a Series C financing.Allena Pharmaceuticals Inc. raised $15 million in a Series A round for nonsystemic oral proteins.Athersys Inc. entered a $20 million standby equity purchase agreement with Aspire Capital Fund LLC.Cadence Pharmaceuticals Inc. is raising $71.25 million in a public stock offering. Read More
"If I can take a public investor over a private investor, I'll take the public investor."– Marc Beer, CEO of Aegerion Pharmaceuticals Inc."Don't think of this as a funding source, think of it as a way into a market."– Randy Berholtz, executive vice president, general counsel and secretary of Apricus Biosciences Inc., on securing financing from foreign governmentsThe cancer vaccine space has been somewhat of a graveyard."– Tom Farrell, CEO of Bellicum Pharmaceuticals Inc. Read More
A congressional conference committee came to terms on a "minibus" bill that includes a 2012 budget for the FDA of nearly $3.8 billion.Sen. Jeff Bingaman introduced the Fair and Immediate Release of Generic Drugs Act, S. 1882, which would attempt to dampen interest in pay-for-delay settlements by modifying the first filer provision to allow other generics to share the 180-day exclusivity. Read More
Total Value in 2011: $8,084M*Number of Deals in 2011: 172Company (Location)Company (Location)Value (M)Type/Product AreaTerms/Details (Date)OctoberBiogen Idec Inc. (Cambridge, Mass.) Read More
Company (Location)Company (Location)Value (M)Type/Product AreaTerms/Details (Date)OctoberGenosys Inc. (Provo, Utah)Equity Labs Inc. (Salt Lake City)ND Read More
Company (Location)Company (Location)Value (M)Type/Product AreaTerms/Details (Date)I. Modified AgreementsOctoberEmerald BioStructures (Bainbridge Island, Wash.)UCB SA (Brussels, Belgium) Read More
